Abiopharma

🔍 LEWIS JOEL (Executive)

Company: GALECTIN THERAPEUTICS INC (GALT)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 84,000 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: false | shares_owned_after: 916,592.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 18,571 shares of Common Stock at $4.1968 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: false | shares_owned_after: 898,021.00 | transaction_form_type: 4 | Footnotes: F1, F1, F4
• Sold 27,731 shares of Common Stock at $3.9069 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: false | shares_owned_after: 870,290.00 | transaction_form_type: 4 | Footnotes: F1, F1, F6
• Sold 37,698 shares of Common Stock at $3.5772 per share (Direct)
  Date: 2026-01-06 | Code: S | equity_swap_involved: false | shares_owned_after: 832,592.00 | transaction_form_type: 4 | Footnotes: F1, F1, F7
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: as USTA custodian for a minor child | shares_owned_after: 2,000.00 | Footnotes: F3
• Sold 84,000 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-02 | Code: M | Exercise: 2026-01-01 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2, F5, F5, F5

Footnotes:

• F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
• F2: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.
• F3: These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.
• F4: The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
• F5: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.
• F6: The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
• F7: The shares were sold in multiple transactions at prices ranging from $3.36 to $3.79. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.